Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Masahiro Iinuma
Institution:
National Hospital Organization Mito Medical Center
Observed institution:
National Hospital Organization Mito Medical Center
ORCID:
0000-0003-1777-1525
Observed ORCID:
0000-0003-1777-1525
OpenAlex ID:
A5075529362
Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
·
Cancer Research Communications
·
2
PDF
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First‐Line, Immune‐Based Combinations
2026
·
Hiromichi Sakurai
, Masanobu Shiga
, et al.
·
Cancer Reports
Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Supplemental Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Data from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Table 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Table 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025
·
Bunpei Isoda
, Masanobu Shiga
, et al.
Show more works
View as search
Works count:
11
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type